Mirum Pharmaceuticals, Inc.

As of June 18, 2025, Mirum Pharmaceuticals is in a bullish trend supported by strong technical indicators, despite mixed signals from the RSI, and has significantly outperformed the S&P 500 with year-to-date and one-year returns of 82.15% and 98.73%, respectively.

As of August 5, 2021, Mirum Pharmaceuticals, Inc. is considered risky and overvalued with a Price to Book Value of 9.85 and an EV to Sales ratio of 6.14, despite strong stock performance, as indicated by a year-to-date return of 82.15% compared to the S&P 500's 12.22%.

Mirum Pharmaceuticals, Inc. reported strong financial results for the quarter ending June 2025, achieving record operating cash flow and net sales. The company improved its liquidity and reduced raw material costs, although it faced challenges with pre-tax and net profits. Overall, it demonstrates resilience and potential for future growth.

As of August 5, 2021, Mirum Pharmaceuticals is considered risky and overvalued with a Price to Book Value of 9.85 and an EV to EBITDA of -44.55, especially when compared to peers like Catalyst Pharmaceuticals and CureVac, despite a strong stock performance of 56.86% over the past year.

As of June 18, 2025, Mirum Pharmaceuticals, Inc. shows a bullish trend supported by strong MACD and KST indicators, though the monthly RSI presents a bearish signal that tempers the overall outlook.

As of March 2022, the management team of Mirum Pharmaceuticals, Inc. includes Chairman Michael Grey, CEO Christopher Peetz, and several independent directors: Tiba Aynechi, Laura Brege, Laurent Fischer, Patrick Heron, and Edward Mathers.

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing therapies for liver diseases. As of March 2025, it reported net sales of $112 million and a net loss of $15 million, with a market cap of approximately $2.51 billion.

As of Jun 18, Mirum Pharmaceuticals, Inc. has a market capitalization of $2.51 billion, with net sales of $379.25 million and a net profit of -$77.34 million over the latest four quarters. The company's balance sheet shows shareholder's funds of $225.64 million and total assets of $670.75 million.